We’re proud to be adding another effective treatment for erectile dysfunction (ED) to our range of medications. Vitaros, a topical cream formulation of alprostadil, was recently launched by Takeda to treat impotence. The treatment was first approved for marketing by Health Canada back in November 2010, and was officially launched in the UK in June, 2014.
The medication is available in 2 dosage strengths of 200 and 300mcg alprostadil in 100mg of cream. It is used to treat ED in men aged 18 and over. ED is the inability to achieve or sustain an erection sufficient for sex.
The cream formulation is applied topically to the tip of the penis. It incorporates a skin-permeation enhancer, which helps absorption of the active ingredient though the glans. Once applied, it starts to take effect within 5 to 30 minutes, and lasts for one to two hours. However, the time it takes to work will differ from person to person.
Vitaros differs from other erectile dysfunction treatments like Viagra and Cialis, which are taken in the form of a tablet. It has been manufactured for direct application and to offer a quick onset with significant efficacy.
In clinical trials, the medication was studied in over 3,000 patients and showed positive responses to the treatment. As men suffering with ED usually have other medical problems, Viatros was also assessed in these populations.
Men with ED and accompanying conditions such as diabetes or heart problems, or those who had undergone a prostatectomy, also experienced greater erectile function while taking Vitaros. In general, they tolerated the treatment really well.
Since it’s a topical application, the treatment has fewer side effects and enables men who do not react well to oral ED treatments to have another option. Overall, it has an excellent side effect profile.
Men who are resistant to using oral medications or have certain medical conditions that may exclude them from other ED treatments now have an additional choice in Vitaros.